RxDoctor Payments Data

Lindsay Hughes, DO

Family Medicine · Wind Gap, PANPI 1003143280

Payments from drug & device makers

$1,097in general payments, 2019–2025

Across 90 payments — averaging $12.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • AstraZeneca$142
  • Teva Pharmaceuticals USA, Inc.$125
  • Abbott$76
  • Sanofi-aventis U.S. LLC$59
  • GSK$56
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$1,05296%
  • Education$444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,097 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,410
Medicare patients
402
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$56,155
EliquisApixaban31$33,656
JardianceEmpagliflozin17$22,461
FarxigaDapagliflozin Propanediol20$22,128
XareltoRivaroxaban14$16,885
Breo ElliptaFluticasone/Vilanterol11$11,429
VascepaIcosapent Ethyl11$4,449
Atorvastatin Calcium289$3,055
Albuterol Sulfate HfaAlbuterol Sulfate98$2,975
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,325
SynthroidLevothyroxine Sodium31$2,146
Levothyroxine Sodium178$1,983
Gabapentin81$1,603
Omeprazole81$1,542
Lisinopril151$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$56,15544 claims
AstraZenecaFarxiga$142$22,12820 claims
GSKBreo Ellipta$56$11,42911 claims
AbbVieSynthroid$554$2,14631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Wind Gap

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →